Scholarlink

Purpose of Review <p>This review aims to provide a comprehensive overview of DNA vaccine platforms developed against SARS-CoV-2 after providing information on the COVID-19 agent SARS-CoV-2. The review focuses on the mechanisms of action of DNA vaccines, their immunological benefits and their advantages over other vaccine technologies. The potential role of these platforms in current and future pandemic preparedness is also addressed.</p> Recent Findings <p>During the COVID-19 pandemic, DNA vaccines emerged as an alternative to conventional and other modern vaccine technologies. Unlike mRNA vaccines, DNA vaccines show better thermal stability and allow for distribution without the need for a cold chain. Accumulating evidence has shown that DNA vaccines can elicit strong humoral and cellular immune responses, which are essential for protection against SARS-CoV-2. In addition, their rapid design, scalability and favorable safety profile have supported their evaluation for wider application in public health.</p> Summary <p>SARS-CoV-2 is a virus that emerged in Wuhan, China in late 2019 and quickly caused a global pandemic. The virus leads to COVID-19, a disease with symptoms ranging from mild to severe and even fatal outcomes. Since the pandemic’s onset, many vaccine platforms have been used to develop an effective and safe vaccine against the SARS-CoV-2 virus, to prevent severe clinical manifestations and economic losses. DNA vaccines offer a versatile, safe, and scalable approach to combating infectious diseases including COVID-19. Their stability, ease of production, and ability to generate cellular and humoral immune responses make them highly attractive for both pandemic control and long-term global immunization strategies. Moreover, ongoing research and clinical evaluation of DNA vaccine platforms are essential to fully utilize their potential in current and future pandemics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DNA Vaccines, an Innovative Vaccine Platform against COVID-19

  • 期刊论文

  • 发表日期：

    2025年8月8日

查看全文
  • İrem Yavuz,
  • Mert Döşkaya,
  • Muhammet Karakavuk,
  • Aysu Değirmenci Döşkaya,
  • Adnan Yüksel Gürüz,
  • Hüseyin Can

摘要

Purpose of Review

This review aims to provide a comprehensive overview of DNA vaccine platforms developed against SARS-CoV-2 after providing information on the COVID-19 agent SARS-CoV-2. The review focuses on the mechanisms of action of DNA vaccines, their immunological benefits and their advantages over other vaccine technologies. The potential role of these platforms in current and future pandemic preparedness is also addressed.

Recent Findings

During the COVID-19 pandemic, DNA vaccines emerged as an alternative to conventional and other modern vaccine technologies. Unlike mRNA vaccines, DNA vaccines show better thermal stability and allow for distribution without the need for a cold chain. Accumulating evidence has shown that DNA vaccines can elicit strong humoral and cellular immune responses, which are essential for protection against SARS-CoV-2. In addition, their rapid design, scalability and favorable safety profile have supported their evaluation for wider application in public health.

Summary

SARS-CoV-2 is a virus that emerged in Wuhan, China in late 2019 and quickly caused a global pandemic. The virus leads to COVID-19, a disease with symptoms ranging from mild to severe and even fatal outcomes. Since the pandemic’s onset, many vaccine platforms have been used to develop an effective and safe vaccine against the SARS-CoV-2 virus, to prevent severe clinical manifestations and economic losses. DNA vaccines offer a versatile, safe, and scalable approach to combating infectious diseases including COVID-19. Their stability, ease of production, and ability to generate cellular and humoral immune responses make them highly attractive for both pandemic control and long-term global immunization strategies. Moreover, ongoing research and clinical evaluation of DNA vaccine platforms are essential to fully utilize their potential in current and future pandemics.